GN 4474

Drug Profile

GN 4474

Alternative Names: GN-4474

Latest Information Update: 05 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Atterx Biotherapeutics
  • Class Antibacterials; Bacteria; Bacterial toxins
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 30 Aug 2017 Preclinical trials in Bacterial infections in USA before August 2017 (Atterx Biotherapeutics pipeline, August 2017)
  • 30 Aug 2017 Atterx Biotherapeutics announces intention to submit IND to US FDA for Bacterial infections in 2017 (Atterx Biotherapeutics pipeline, August 2017)
  • 30 Aug 2017 Antimicrobial data from preclinical studies in Bacterial indications released by Atterx Biotherapeutics before August 2017 (Atterx Biotherapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top